毕得医药(688073) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 262,669,977.50, representing a year-over-year increase of 4.05%[5] - Net profit attributable to shareholders decreased by 29.39% to CNY 26,074,943.00 compared to the same period last year[5] - The basic and diluted earnings per share were both CNY 0.29, reflecting a decline of 29.27% year-over-year[5] - Total operating revenue for Q1 2024 was CNY 262,669,977.50, an increase of 4.87% compared to CNY 252,455,900.29 in Q1 2023[18] - Net profit for Q1 2024 was CNY 26,074,943.00, a decrease of 29.3% from CNY 36,928,240.19 in Q1 2023[19] - Earnings per share for Q1 2024 was CNY 0.29, down from CNY 0.41 in Q1 2023[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,381,919,508.50, a decrease of 1.37% from the end of the previous year[6] - Total assets as of Q1 2024 amounted to CNY 2,381,919,508.50, a slight decrease from CNY 2,415,027,980.82 at the end of the previous period[16] - Total liabilities for Q1 2024 were CNY 336,679,198.66, compared to CNY 325,485,828.49 in the previous period, reflecting an increase of 4.0%[16] - Total non-current assets decreased to CNY 142,171,264.41 from CNY 153,861,833.35, indicating a decline of 7.6%[16] Equity and Shareholder Information - The total equity attributable to shareholders decreased by 2.12% to CNY 2,045,240,309.84 compared to the end of the previous year[6] - The company’s total equity decreased to CNY 2,045,240,309.84 from CNY 2,089,542,152.33, reflecting a decline of 2.12%[16] - Total number of common shareholders at the end of the reporting period was 4,933[11] - The top 10 shareholders collectively hold 47.03% of the company's shares, with the largest shareholder being Dai Lan, holding 32.6%[12] - The company has a share repurchase account holding 2,129,043 shares, representing 2.34% of total shares[12] - The company is actively managing its shareholder relationships, with no reported related party transactions among other shareholders[12] Cash Flow - The net cash flow from operating activities was CNY 48,167,499.32, with no comparative data available[5] - Cash inflow from operating activities for Q1 2024 was $283.64 million, an increase of 3.0% compared to $274.83 million in Q1 2023[21] - Net cash flow from operating activities for Q1 2024 was $48.17 million, a significant recovery from a net outflow of $21.46 million in Q1 2023[21] - Cash outflow for purchasing goods and services decreased to $162.27 million in Q1 2024 from $238.12 million in Q1 2023, representing a reduction of 31.8%[21] - Cash inflow from investment activities was $1.36 million in Q1 2024, down from $3.47 million in Q1 2023, indicating a decline of 60.8%[22] - Net cash flow from investment activities was -$0.95 million in Q1 2024, an improvement from -$7.00 million in Q1 2023[22] - Cash inflow from financing activities increased significantly to $39.75 million in Q1 2024 from $0.19 million in Q1 2023[22] - Net cash flow from financing activities was -$37.13 million in Q1 2024, worsening from -$3.05 million in Q1 2023[22] - The ending cash and cash equivalents balance for Q1 2024 was $1.27 billion, compared to $1.46 billion at the end of Q1 2023[22] - The company experienced a foreign exchange impact of -$0.92 million on cash and cash equivalents in Q1 2024, compared to -$0.17 million in Q1 2023[22] Expenses and Costs - Research and development expenses totaled CNY 15,420,297.35, accounting for 5.87% of revenue, down 0.53 percentage points from the previous year[6] - The company experienced a decline in net profit primarily due to the growth rate of costs and expenses exceeding that of revenue[9] - Total operating costs for Q1 2024 were CNY 225,411,993.32, up 10.83% from CNY 203,401,460.75 in Q1 2023[18] - The company reported a financial expense of CNY -7,645,483.44 in Q1 2024, compared to CNY -2,676,576.18 in Q1 2023, showing an increase in financial costs[18] Other Information - The company is focused on expanding its market presence and developing new products and technologies[11] - The company reported cash and cash equivalents of approximately ¥1.28 billion, an increase from ¥1.27 billion at the end of 2023[14] - Total current assets amounted to approximately ¥2.24 billion, a slight decrease from ¥2.26 billion in the previous period[14] - Inventory decreased to approximately ¥670.41 million from ¥699.43 million[14] - The company’s deferred income tax assets were CNY 18,841,531.42, slightly up from CNY 18,360,441.47 in the previous period[16] - The company did not adopt new accounting standards for the first quarter of 2024[23]